Orbimed News and Activities

Orbimed has a direct presence in 2 countries.

They are in:

• Fund50%
• Biotechnology50%

View the org chart displaying its 48 main executives

Most searched biographies at Orbimed

• Sven Borho, Managing Partner
• Trey Block, Chief Financial Officer
• Daniel Rhee, Chief Technology Officer

Create your alert
to follow the executive moves at Orbimed.

Orbimed has 1,642 competitors including Griffin Gaming Partners (United States (USA)), BlackRock (United States (USA)) and KKR (United States (USA)).

Popular M&A news in Fund

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (posted on June 3 2026).
• Prime Capital Financial has acquired Access Capital Partners (posted on June 2 2026).
• Frazier Healthcare Partners has acquired Altruix (posted on May 29 2026).

Popular contacts in Fund

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer at Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director at Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director at KKR

Learn more about the Fund industry

Press releases by Orbimed

• Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
• Lilly announces three acquisitions to build infectious disease portfolio
• Biobeat Secures $50 Million Series B Financing to Advance Commercialization of its Patch-worn, Cuffless  24-hour Ambulatory Blood Pressure Monitor - biobeat
• Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
• Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
• Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
• UCB to Acquire Candid Therapeutics, Building Upon Its Existing Immunology Pipeline With Novel T-cell Engagers
• Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer | Sidewinder Therapeutics
• Insilico Medicine Announces Global R&D Collaboration with Lilly
• Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) — Terns Pharmaceuticals, Inc.
• View more press releases Close

Social media about Orbimed

• Orbimed on Wikipedia, Google News & Yahoo Finance
• Orbimed on LinkedIn, X (Twitter) & YouTube